ArticleBiotechnology and applied biochemistry2026
Constructing Haloarchaeal MVA Pathway in Serratia marcescens for Synthesis of Ocimene.
Article in Biotechnology and applied biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Constructing Haloarchaeal MVA Pathway in Serratia marcescens for Synthesis of Ocimene.Biotechnology and applied biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocimene, a valuable monoterpene with applications in agriculture, pharmaceuticals, and fragrances, is challenging to produce at high yields using traditional microbial platforms such as Escherichia coli and Saccharomyces cerevisiae due to monoterpene toxicity. In this study, Serratia marcescens, known for its tolerance to organic solvents and terpenes, was engineered to synthesize ocimene through the haloarchaeal mevalonate (MVA) pathway. We optimized key enzymes, promoters, and pathway construction to enhance production. The engineered strain successfully produced ocimene, with a yield of 436 mg·L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.